Last reviewed · How we verify
lorundrostat Dose 1
Lorundrostat is a selective, reversible inhibitor of 11β-HSD1.
Lorundrostat is a selective, reversible inhibitor of 11β-HSD1. Used for Congestive heart failure.
At a glance
| Generic name | lorundrostat Dose 1 |
|---|---|
| Sponsor | Mineralys Therapeutics Inc. |
| Drug class | 11β-HSD1 inhibitor |
| Target | 11β-HSD1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic disorders |
| Phase | Phase 3 |
Mechanism of action
By inhibiting 11β-HSD1, lorundrostat reduces cortisol production in the body, which can help alleviate symptoms of certain conditions.
Approved indications
- Congestive heart failure
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen (PHASE2)
- Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lorundrostat Dose 1 CI brief — competitive landscape report
- lorundrostat Dose 1 updates RSS · CI watch RSS
- Mineralys Therapeutics Inc. portfolio CI